

**SARS-CoV-2 infection elicits a rapid neutralizing antibody response that
correlates with disease severity**

Benjamin Trinité¹, Ferran Tarrés-Freixas¹, Jordi Rodon², Edwards Pradenas¹,
Victor Urrea¹, Silvia Marfil¹, Maria Luisa Rodriguez de la Concepción¹, Carlos
Ávila-Nieto¹, Carmen Aguilar-Gurrieri¹, Ana Barajas¹, Raquel Ortiz¹, Roger
Paredes^{1,3}, Lourdes Mateu³, Alfonso Valencia⁴, Victor Guallar^{4,5}, Lidia Ruiz¹,
Eulàlia Grau¹, Marta Massanella¹, Jordi Puig³, Anna Chamorro³, Nuria
Izquierdo-Useros¹, Joaquim Segalés^{2,6}, Bonaventura Clotet^{1,3,7}, Jorge Carrillo¹,
Júlia Vergara-Alert², Julià Blanco^{1,7,*}

¹IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute
(IGTP), Can Ruti Campus, 08916, Badalona, Catalonia, Spain

²IRTA Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de
la UAB, 08193 Bellaterra, Catalonia, Spain

³Infectious Diseases Department, Fight against AIDS Foundation (FLS),
Germans Trias i Pujol Hospital, Badalona, Catalonia, Spain


⁴Barcelona Supercomputing Center, Barcelona, Catalonia, Spain

⁵Catalan Institution for Research and Advanced Studies (ICREA), Barcelona,
Catalonia, Spain


⁶UAB, CReSA (IRTA-UAB), Campus de la UAB, 08193 Bellaterra, (Cerdanyola
del Vallès), Catalonia, Spain

⁷University of Vic–Central University of Catalonia (UVic-UCC), Vic, Catalonia,
Spain

SUPPLEMENTARY MATERIAL



Supplementary Figure 1. Patients classification according to symptoms



Supplementary Figure 2. Analysis of neutralizing activity according to drug combinations.